

Special Issue

What's behind the Scenes? New Insights in Endometrial Cancer Management and Risk Stratification

Message from the Guest Editor

Endometrial cancer (EC) is the fourth most widespread malignancy in developed countries. A further fundamental step was the transition from tumor DNA sequencing to the immunohistochemical (IHC) analysis of the molecular classification with the ProMisE study, which outlined four different prognostic EC sub-groups almost superimposable to the TCGA genomic classes. Other molecular markers have been investigated to further understand the remaining knowledge gaps. Recently, on these bases, the ESGO/ESTRO/ESP guidelines classification system was introduced, combining the pathological and clinical features with the new molecular information in EC risk stratification and management. Waiting for the result of the PORTEC 4a study that will define the correct therapeutic management with adjuvant therapy and the EUGENIE trial that will indicate the proper surgical staging for each molecular class, the aim of this Special Issue is focused on describing the updates related to the classification and management of EC in the context of this new molecular era.

Guest Editor

Dr. Emanuele Perrone

Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC
Ginecologia Oncologica, Dipartimento per la salute della Donna e del
Bambino e della Salute Pubblica, Roma, Italy

Deadline for manuscript submissions

20 October 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/144641

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)